CTOs on the Move

Tarsus Pharmaceuticals

www.tarsusrx.com

 
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tarsusrx.com
  • 15440 Laguna Canyon Road Suite 160
    Irvine, CA USA 92618
  • Phone: 949.409.9820

Executives

Name Title Contact Details

Funding

Tarsus Pharmaceuticals raised $60M on 01/08/2020
Tarsus Pharmaceuticals raised $75.6M on 05/03/2022

Similar Companies

Circle Pharma

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015.

UQUIFA

UQUIFA is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical and animal health industries globally

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Adjuvants Plus Inc

Adjuvants Plus Inc is a Kingsville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cytheris

Cytheris is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.